Cargando…
Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020
New Zealand (Aotearoa) experienced a Neisseria meningitidis serogroup B epidemic during 1991–2006, and incidence remains twice that of other high-income countries. We reviewed clinical, laboratory, and immunization data for children <15 years of age with laboratory-confirmed invasive meningococca...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045698/ https://www.ncbi.nlm.nih.gov/pubmed/36957984 http://dx.doi.org/10.3201/eid2904.221397 |
_version_ | 1784913668646895616 |
---|---|
author | Burton, Cameron Best, Emma Broom, Matthew Heffernan, Helen Briggs, Simon Webb, Rachel |
author_facet | Burton, Cameron Best, Emma Broom, Matthew Heffernan, Helen Briggs, Simon Webb, Rachel |
author_sort | Burton, Cameron |
collection | PubMed |
description | New Zealand (Aotearoa) experienced a Neisseria meningitidis serogroup B epidemic during 1991–2006, and incidence remains twice that of other high-income countries. We reviewed clinical, laboratory, and immunization data for children <15 years of age with laboratory-confirmed invasive meningococcal disease in Auckland, New Zealand, during January 1, 2004–December 31, 2020. Of 319 cases in 318 children, 4.1% died, and 23.6% with follow-up data experienced sequelae. Children of Māori and Pacific ethnicity and those living in the most deprived areas were overrepresented. Eighty-one percent were positive for N. meningitidis serogroup B, 8.6% for serogroup W, 6.3% for serogroup C, and 3.7% for serogroup Y. Seventy-nine percent had bacteremia, and 63.9% had meningitis. In New Zealand, Māori and Pacific children are disproportionately affected by this preventable disease. N. meningitidis serogroup B vaccine should be included in the New Zealand National Immunization Schedule to address this persistent health inequity. |
format | Online Article Text |
id | pubmed-10045698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-100456982023-04-01 Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020 Burton, Cameron Best, Emma Broom, Matthew Heffernan, Helen Briggs, Simon Webb, Rachel Emerg Infect Dis Synopsis New Zealand (Aotearoa) experienced a Neisseria meningitidis serogroup B epidemic during 1991–2006, and incidence remains twice that of other high-income countries. We reviewed clinical, laboratory, and immunization data for children <15 years of age with laboratory-confirmed invasive meningococcal disease in Auckland, New Zealand, during January 1, 2004–December 31, 2020. Of 319 cases in 318 children, 4.1% died, and 23.6% with follow-up data experienced sequelae. Children of Māori and Pacific ethnicity and those living in the most deprived areas were overrepresented. Eighty-one percent were positive for N. meningitidis serogroup B, 8.6% for serogroup W, 6.3% for serogroup C, and 3.7% for serogroup Y. Seventy-nine percent had bacteremia, and 63.9% had meningitis. In New Zealand, Māori and Pacific children are disproportionately affected by this preventable disease. N. meningitidis serogroup B vaccine should be included in the New Zealand National Immunization Schedule to address this persistent health inequity. Centers for Disease Control and Prevention 2023-04 /pmc/articles/PMC10045698/ /pubmed/36957984 http://dx.doi.org/10.3201/eid2904.221397 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Synopsis Burton, Cameron Best, Emma Broom, Matthew Heffernan, Helen Briggs, Simon Webb, Rachel Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020 |
title | Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020 |
title_full | Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020 |
title_fullStr | Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020 |
title_full_unstemmed | Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020 |
title_short | Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020 |
title_sort | pediatric invasive meningococcal disease, auckland, new zealand (aotearoa), 2004–2020 |
topic | Synopsis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045698/ https://www.ncbi.nlm.nih.gov/pubmed/36957984 http://dx.doi.org/10.3201/eid2904.221397 |
work_keys_str_mv | AT burtoncameron pediatricinvasivemeningococcaldiseaseaucklandnewzealandaotearoa20042020 AT bestemma pediatricinvasivemeningococcaldiseaseaucklandnewzealandaotearoa20042020 AT broommatthew pediatricinvasivemeningococcaldiseaseaucklandnewzealandaotearoa20042020 AT heffernanhelen pediatricinvasivemeningococcaldiseaseaucklandnewzealandaotearoa20042020 AT briggssimon pediatricinvasivemeningococcaldiseaseaucklandnewzealandaotearoa20042020 AT webbrachel pediatricinvasivemeningococcaldiseaseaucklandnewzealandaotearoa20042020 |